Results 141 to 150 of about 214,611 (264)

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa   +8 more
wiley   +1 more source

Transport–Reaction–Signal Coupling in Lateral Flow Assays for Next‐Generation Point‐of‐Care Diagnostics

Advanced Science, EarlyView.
Lateral flow assays are evolving into interdisciplinary, system‐level sensing platforms. Recent innovations are deconstructed through coupled phases of mass transfer, reaction, and signal transduction, revealing interdependence across porous materials, interfacial chemistry, nanolabels, readout devices, and data‐enabled analysis.
Yan Pan, Yuewei Li, Chao Mi, Zhengwen Yang, Lana McClements, Steven J. Langford, Jiayan Liao   +6 more
wiley   +1 more source

HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.

, 2012
A rapid, reliable method for distinguishing tumors or metastases that overexpress human epidermal growth factor receptor 2 (HER2) from those that do not is highly desired for individualizing therapy and predicting prognoses.
Jonas Grafström (145905), Erik Samén (18653320), Finn Dunås (12222861), Qing Cheng (18684607), Hanna-Stina Martinsson Ahlzén (19848630), Stefan Ståhl (154271), Sharon Stone-Elander (145935), Li Lu (68660), Elias Arnér (18684970), Helena Wållberg (3765691), Katarina Johansson (145928), Jan-Olov Thorell (145917), Maria Hägg Olofsson (15067675)   +12 more
core   +1 more source

HER2 breast cancer therapies: a review

, 2009
Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25%
Conleth G Murphy, Shanu Modi
core  

Transfer RNA‐Derived Small RNA‐5’tiRNAGln Drives HNRNPC Phase Separation to Promote Breast Cancer Bone Metastasis by Regulating IGF1R

Advanced Science, EarlyView.
This study reveals that 5'tiRNA‐Gln interacts with hnRNPC to promote IGF1R liquid‐liquid phase separation, which drives ERK1/2 signaling activation, EMT, and breast cancer bone metastasis. These findings highlight a novel mechanism of breast cancer bone metastasis and potential therapeutic target in metastatic breast cancer.
Bingnan Wang, Dongsong Liu, Xiaozhi Fan, Jiale Fan, Xuesi liu, Yu Wang, Zixin Wang, Mo Cheng, Ping Zhou, Wangjun Yan   +9 more
wiley   +1 more source

Decoding Biomolecular Phase Separation: From Physiological Roles to Pathological Mechanisms and Therapeutic Biomaterials Design

Advanced Science, EarlyView.
This review systematically elaborates on the mechanisms underlying physiological regulation and pathological dysregulation of biomolecular phase separation. It also summarizes advances in phase‑separation‑targeted therapeutic strategies and the design of functional biomaterials inspired by this process.
Jiawei Zhu, Jingbo Dong, Qiufang Gong, Xuejiao Song, Zhifa Shen, Chao Liang   +5 more
wiley   +1 more source

HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer. [PDF]

Breast Cancer Res Treat
Raval P, Ding Q, Singh P, Alrohaibani A, Sun H, Ai D, Wanis KN, Zhao M, Chen H, Valero V, Chavez-MacGregor M, Sahin A.   +11 more
europepmc   +1 more source

Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting. J Clin Oncol 30, 2012 (suppl; abstr 586)

, 2012
Background: Relapse Rate (RR) after Adjuvant Trastuzumab (AT) reported in clinical trials is between 15 and 21%. Information on RR and clinical behaviour of HER2-POS metastatic disease after AT outside clinical trials is limited.
AM Molino, on Behalf of Italian North East HER2 STUDY GROUP, MUSTACCHI, GIORGIO, E. Fiorio   +3 more
core  

Growth Differentiation Factor 15 as a Cerebrospinal Fluid Biomarker for the Diagnosis and Prognosis of Leptomeningeal Metastasis

Annals of Neurology, EarlyView.
Objective As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC).
Haoyu Ruan, Jie Li, Fuhai Wang, Lei Zhang, Jie Luo, Yuan Mu, Ting Wang, Yuqing Wu, Jingping Liu, Yunyun Ning, Xuan Deng, Ming Guan, Jian Xu   +12 more
wiley   +1 more source

HER2 Low Expression in Primary Male Breast Cancer [PDF]

Katleen Nobbe,1 Melanie Erices-Leclercq,1 Frank Foerster,2,3 Robert Förster,4 Stephan E Baldus,5 Christian Rudlowski,1,6 Lars Schröder,7 Sabine Lubig1 1Breast Unit, Lutheran Hospital Bergisch Gladbach, Bergisch Gladbach, Germany; 2Department of ...
Schröder L, Erices-Leclercq M, Rudlowski C, Foerster F, Nobbe K, Baldus SE, Lubig S, Förster R   +7 more
core